Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [7862]

NICE final draft guidance adds further treatment option for triple-negative breast cancer

NICE final draft guidance adds further treatment option for triple-negative breast cancer

Researchers find treatment options for patients whose blood cancer relapses after CAR-T

Researchers find treatment options for patients whose blood cancer relapses after CAR-T

NCCN working with Medlive to advance high-quality cancer care in China and worldwide

NCCN working with Medlive to advance high-quality cancer care in China and worldwide

Zanubrutinib receives European commission approval for the treatment of adults with marginal zone lymphoma

Zanubrutinib receives European commission approval for the treatment of adults with marginal zone lymphoma

Identifying the underlying causes of ovarian cancer

Identifying the underlying causes of ovarian cancer

Scientists look for microscopic clues to beating deadly brain tumors

Scientists look for microscopic clues to beating deadly brain tumors

How tumours suppress the development of metastases

How tumours suppress the development of metastases

Preliminary data suggest that ROS1 inhibitor, NVL-520, is well-tolerated and active in non-small cell lung cancer: first results from ARROS-1 phase I clinical trial

Preliminary data suggest that ROS1 inhibitor, NVL-520, is well-tolerated and active in non-small cell lung cancer:...

Anti-cancer drugs, olaparib and adavosertib, work best when given sequentially in patients with advanced tumours driven by DNA damage response mutations: results from phase Ib STAR clinical trial

Anti-cancer drugs, olaparib and adavosertib, work best when given sequentially in patients with advanced tumours...

Experimental drug to treat liver cancer shows evidence of activity with manageable side effects

Experimental drug to treat liver cancer shows evidence of activity with manageable side effects

More from ecancer